ArticleMaterials today. Bio2025
Multienzyme active melanin nanodots for antioxidant-immunomodulatory therapy of hyperoxia lung injury.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.Drug delivery · 2026Review
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Optimized melanin production from marine-associated Bacillus sp. EGY7 as a sustainable precursor of carbon dots for biomedical applications.Bioresources and bioprocessing · 2026Article
- Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.Materials today. Bio · 2026Article
- Alkali-controlled one-pot synthesis of ultrasmall PEGylated polydopamine nanoparticles for diverse biological applications.Journal of nanobiotechnology · 2026Article
- Advances in research on hyperoxia-induced acute lung injury: from pathogenesis to therapy.Frontiers in cell and developmental biology · 2026Review
- Mitochondrial quality control mechanisms as molecular targets for impaired lung development: from fetuses to neonates.Respiratory research · 2025Review
- Inhibition of BRD4 activates the AKT-SIRT3 signaling pathway to suppress apoptosis and attenuate hyperoxia-induced lung injury.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supraphysiological oxygen is the most conventional method of treating patients with acute respiratory failure, but prolonged exposure to hyperoxia generates large amounts of reactive oxygen species (ROS) in the lungs, leading to hyperoxia lung injury (HLI). Nevertheless, there is no safe and effective prevention strategy. Herein, multienzyme active melanin nanodots were developed as an antioxidant-immunomodulatory defense nanoplatform for the treatment of HLI. The prepared nanodots are about 4 nm in size and are mainly composed of carbon, nitrogen and oxygen elements with high stability and multi-enzymatic activity for scavenging various reactive oxygen and reactive nitrogen radicals. Cellular experiments showed that melanin nanodots increased cell viability and ameliorated hyperoxia-induced morphological changes, mitochondrial damage and apoptosis. Meanwhile, by activating the Nrf2/Keap1/HO-1 signaling pathway, the treatment of melanin nanodots significantly inhibited the overproduction of ROS, reduced malondialdehyde, and increased the endogenous antioxidant enzyme activity in BEAS-2B cells. Interestingly, the antioxidant properties of melanin nanodots indirectly promoted the phenotypic shift of macrophages, and reduced hyperoxia-induced inflammatory responses in the damaged environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.